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Abstract: One of the last remaining clinical hurdles in the treatment of people with hemophilia 
is the development of inhibitors. Alloantibodies or autoantibodies directed at coagulation factors 
render the infusion of coagulation factor concentrates ineffective, and alternative means must be 
used to achieve hemostasis. Recombinant factor VIIa (rFVIIa) was developed to control bleed-
ing episodes in hemophilic patients with inhibitors. Clinical efficacy in achieving hemostasis in 
inhibitor patients was demonstrated by a compassionate-use protocol, as well as in randomized 
controlled trials. To date, over 1.5 million doses of rFVIIa have been given to inhibitor patients, 
with an excellent efficacy and safety record. Because of its short half-life, alternative means of 
dosing and infusing rFVIIa have been explored and are reviewed here.
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Introduction
Hemophilia is a disorder characterized by recurrent abnormal bleeding, in particular, 
into muscles and joints. It is caused by a deficiency of various coagulation factors, 
with hemophilia A caused by factor VIII (FVIII) deficiency, hemophilia B caused by 
factor IX (FIX) deficiency, and hemophilia C caused by factor XI (FXI) deficiency. Its 
treatment was revolutionized by the advent of coagulation factor concentrates. These 
concentrates allow hemophilic patients to receive factor replacement in order to achieve 
hemostasis during bleeding episodes, and are also used to prevent bleeding episodes.1 
Factor concentrates were initially derived from human plasma. Viral inactivation tech-
niques were not employed with the early-generation coagulation factor concentrates, 
resulting in the transmission of hepatitis and human immunodeficiency virus infection 
to hemophilic patients.2 Since the mid-1980s, viral inactivation techniques have been 
used for all coagulation factor concentrates. In addition, recombinant FVIII and later, 
recombinant FIX concentrates were developed. As a result, there has been no trans-
mission of clinically relevant infectious agents in coagulation concentrates for over 
20 years.2,3 The last remaining major clinical hurdle in the treatment of hemophilia is the 
development of inhibitors, ie, an immune response to infused coagulation factors.
People with hemophilia are born with a deficient or absent coagulation factor, and 
the infusion of a coagulation factor replacement protein is complicated in some patients 
by the development of an immune response to that protein. The alloantibodies that 
develop are targeted against the infused coagulation factor and are known as inhibitors. 
Inhibitor antibodies rapidly inactivate infused coagulation proteins,   rendering them 
ineffective for achieving hemostasis. Overall, 20%–50% of people with hemophilia 
develop inhibitors.4 Fortunately, these inhibitors are   usually transient and of little clinical Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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significance, but persist in approximately 20% of people with 
hemophilia A and 1% of people with hemophilia B.5,6 In addi-
tion, autoantibodies directed against coagulation factors can 
develop in people with acquired hemophilia. The incidence of 
acquired hemophilia is approximately 1/1,000,000 per year, 
with the elderly and people with other immunologic diseases 
prone to development of the disorder.7 Additional measures 
must be used to achieve hemostasis during bleeding episodes 
in people with inhibitors.
Bypassing factors VIII and IX
Bypassing agents must be used in order to achieve hemostasis 
in patients with inhibitors. These agents take advantage of the 
multiple pathways available to generate a fibrin clot (Figure 1). 
There are two recognized pathways available to convert 
fibrinogen to fibrin. Under normal physiologic   circumstances, 
fibrin is not formed unless blood is exposed to tissue factor, 
which can bind to either inactive or activated factor VII (FVII). 
The majority of FVII circulates in an inactive form, but a 
small percentage circulates in an active form (FVIIa).8 The 
binding of FVIIa to tissue factor creates a complex which can 
produce activated factor X (FXa). FXa, along with its cofac-
tor, activated factor Va (FVa), can then convert prothrombin 
into thrombin (IIa), and thrombin can convert fibrinogen into 
fibrin. This pathway is variously known as the initiation phase, 
tissue factor, or extrinsic pathway of clot formation. Although 
this pathway is sufficient to form some fibrin, it does not form 
a stable fibrin clot under normal physiologic circumstances. 
This is because the tissue factor pathway is rapidly inhibited 
by the tissue factor pathway inhibitor (TFPI). In order to form 
a stable fibrin clot, additional fibrin must be generated by the 
propagation phase/intrinsic coagulation pathway.9 The small 
amount of thrombin generated by the tissue factor pathway has 
many functions, one of which is the formation of activated FXI 
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Figure 1 Tissue factor initiated blood coagulation. During the initiation phase, blood becomes exposed to TF-bearing cells. Inactivated Factor VII and VIIa compete for binding 
with TF. Once the TF: VIIa complex is formed, X is activated to factor Xa. Factor Xa and Va form the prothrombinase complex which converts prothrombin (II) to thrombin 
(IIa). The nanomolar amount of thrombin generated can activate platelets, Factor V, VIIIa, and XIa. Small amounts of fibrinogen are converted to fibrin by thrombin, but not 
enough to form a stable clot. The initiation phase is rapidly inhibited by TFPI. In order to form a stable clot, a burst in thrombin activity is required, which occurs through 
the propagation phase. XIa can activate IXa, with the resulting IXa: VIIIa forming the Xase complex. This complex can form Xa. Additional prothrombinase is formed, which 
activates thrombin which can feed back and generate more XIa, thus creating a burst in thrombin activity. In addition to generating a sufficient amount of fibrin for stable clot 
formation, the burst in thrombin activity also generates TAFI which inhibits fibrinolysis. Fibrin is cross-linked by XIIIa, which is activated by thrombin. Solid arrows indicate 
activation. Dashed arrows indicate inhibition. Blue equals the initiation phase. Red equals the propagation phase. Purple equals both. Green arrows indicate substances activated 
by thrombin. Brown indicates inhibitors of coagulation.
Abbreviations: TAFI, thrombin-activatable fibrinolysis inhibitor; TF, tissue factor; TFPI, tissue factor pathway inhibitor; VIIa, activated factor VII; X, factor X; Va, factor Va; 
VIIIa, activated factor VIII; XIa, activated factor XI; IXa, activated factor IX.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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(FXIa). FXIa can then generate activated FIX (FIXa). FIXa 
along with its cofactor, activated FVIII (FVIIIa), forms an 
Xase (tenase) complex which activates FX (FXa). FXa along 
with its cofactor, FVa, forms the prothrombinase complex 
which generates more thrombin which can feed back and 
generate more FXIa, as well as convert fibrinogen to fibrin.8,9 
The principal role of the coagulation cofactors, FVIIIa and 
FVa, is to cause the formation of the Xase and prothrombinase 
complex on the phospholipid surfaces of cells and platelets. 
This increases the rate of FXa and thrombin conversion by 
several orders of magnitude.10
The positive feedback loop of the propagation phase 
is necessary for a burst in thrombin generation which is 
required for the formation of a stable fibrin clot. Patients with 
hemophilia do not bleed because they cannot generate fibrin, 
but because they cannot generate the large burst in thrombin 
necessary to form a stable fibrin clot. Hemophilic patients 
with inhibitors cannot restore their ability to generate a burst 
in thrombin by infusions of the deficient coagulation factor 
because the antibody directed against the coagulation factor 
renders it inactive. In order to generate the required burst in 
thrombin activity, one must bypass the intrinsic coagulation 
cascade and take advantage of the tissue factor pathway.8,9
Prothrombin complex concentrates 
and factor VIIa
Early attempts at the generation of a FIX complex concen-
trate in the late 1960s resulted in a concentrate that not only 
contained FIX, but also factor II (thrombin), FVII, and FX.11 
Because factors II, VII, and X are key components of the tis-
sue factor pathway, FIX concentrates known as prothrombin 
complex concentrate (PCC) were used to treat hemophilic 
patients with inhibitors.11 An alternative method of treatment 
was porcine FVIII. Although PCCs were successful in achiev-
ing hemostasis in patients with inhibitors, they were not as 
successful as using specific factor concentrates in noninhibi-
tor patients. This situation was improved by the generation of 
PCCs in which the coagulation factors were activated. The 
activated prothrombin complex concentrates (aPCCs) were 
able to achieve hemostasis in approximately 60% of bleeding 
episodes in inhibitor patients.11 However, PCCs developed 
before the mid-1980s were complicated by the transmission 
of infectious agents, and high doses of PCCs and aPCCs 
were associated with thrombosis.12 In addition, the PCCs and 
aPCCs contain FIX and trace amounts of FVIII, which could 
lead to an anamnestic response in inhibitor patients.12
Several lines of evidence pointed toward FVIIa as the 
principal bypassing agent in PCCs and aPCCs. Following 
an infusion of PCCs in hemophilia B patients, FVII activity 
rose significantly more than that of FIXa or FXa.13 Secondly, 
the ratio of FVIIa/FVII is high in PCCs and even more so in 
aPCCs.13 This led several investigators, the principal of whom 
was Ulla Hedner, to suspect that FVIIa alone could bypass 
the need for FVIII or FIX in order to achieve hemostasis 
in hemophilic patients with inhibitors. In the early 1980s, 
Hedner and Kiesel were able to develop a FVIIa concentrate 
from donated human plasma.14 They reported on the first 
successful experience using this agent in two patients with 
hemophilia and high titer inhibitors in 1983.13
Factor VIIa is able to restore the ability of inhibitor 
patients to generate a burst in thrombin by at least two 
mechanisms9,15 (Figure 2). Infusions of FVIIa increase the 
relative amount of FVIIa compared with inactive FVII. This 
increases the likelihood of FVIIa binding to tissue factor, 
thereby increasing the generation of FXa and thrombin.9 This 
process can still be inhibited by TFPI. Secondly, supraphysi-
ologic concentrations of FVIIa can generate Xa on the surface 
of activated platelets in a tissue factor-independent fashion. 
This pathway is not inhibited by TFPI or FVIII/FIX inhibi-
tory antibodies.15 Via these mechanisms, FVIIa can generate 
a burst in thrombin without the need for the intrinsic cascade 
and factors VIII, IX, and XI. In addition, the localization of 
FVIIa activity to the activated platelet surface reduces the 
risk of systemic thrombin generation.
The production of FVIIa from human plasma proved to 
be a cumbersome task, and carried the potential risk of trans-
mission of infectious agents (although viral inactivation pro-
cesses were being developed by this time).14 With the advent 
of molecular biology and genetic engineering, the ability 
to clone and express genes was being developed. A review 
of the manufacturing process for rFVIIa (Novoseven®) is 
described by Persson et al16 and summarized below:
FVII cDNA was cloned from a phage-lambda human cDNA 
expression library using radio-labeled antibody against FVII. 
Because FVII undergoes extensive posttranslational modifica-
tion, a mammalian cell line was required to produce rFVII. A 
baby hamster kidney cell line was transfected with a plasmid 
containing the human FVII cDNA and cloned. Working cell 
lines from the master cell line are then grown in biofermenters 
in a growth medium containing New Zealand derived calf serum 
and vitamin K. Medium is then harvested from the biofermenter 
and rFVII is purified using anion exchange and monoclonal 
antibody columns. rFVII is autoactivated into rFVIIa during 
the process of purification. Detergents are added during the 
purification process to inactivate any enveloped viruses. The 
current formulation of rFVIIa (Novoseven RT) contains NaCl, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Figure 2a Cell-mediated model of normal coagulation. The TF: VIIa complex forms on a TF-bearing cell. Prothrombinase then forms on this cell membrane to generate 
thrombin. Additional thrombin is propagated through XIa and the Xase and prothrombinase complexes formed on the surface of activated platelets.
Abbreviations: TF, tissue factor; VIIa, activated factor VII; XIa, activated factor XI.
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Figure 2b Cell-mediated model in a hemophilic patient with an inhibitor. The TF:VIIa complex and prothrombinase complex can generate thrombin, however the propagation 
phase cannot occur due to the absence of factors VIII or IX. TFPI rapidly inhibits the TF:VIIa complex.
Abbreviations: TF, tissue factor; VIIa, activated factor VII; TFPI, tissue factor pathway inhibitor.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Ca Cl2, glycylglycine, polysorbate 80, mannitol, sucrose, and 
methionine. After the rFVIIa is formulated, it is dispensed into 
vials, and freeze-dried.
Pharmacokinetics of rFVIIa
Preclinical studies of rFVIIa in a hemophilic dog model dem-
onstrated the ability of rFVIIa to correct the hemostatic defect 
in dogs subjected to a standardized bleeding assay.17 Pharma-
cokinetic studies of rFVIIa have been hampered by the lack 
of an assay specific for rFVIIa. As a surrogate, FVII clotting 
activity has been used. Studies in healthy adult volunteers anti-
coagulated with acenocoumarol, adult patients with hemophilia 
A and B, pediatric patients with hemophilia, and patients with 
cirrhosis were undertaken.18,19 The studies revealed a median 
elimination half-life of 2.45 hours in adults and 1.3 hours in 
children. The median clearance in adults was 34.5 mL/kg/hour 
and 67 mL/kg/hour in children. The pharmacokinetic param-
eters were similar in healthy adult volunteers to those in patients 
with hemophilia, as well as bleeding and nonbleeding patients. 
These preclinical and pharmacokinetic studies assisted in the 
development of appropriate dosing during the clinical trials of 
rFVIIa. A more recent evaluation of radiolabeled rFVIIa in a 
mouse model revealed extensive extravascular accumulation, 
particularly in the liver and in calcified cartilage.20 This model 
suggests that rFVIIa may have biologic effects that last much 
longer than its measurable intravascular half-life.
Clinical studies of rFVIIa
In 1988 Ulla Hedner described the first use of rFVIIa in a 
patient with congenital hemophilia A and a high titer inhibitor.21 
rFVIIa was given prior to and following a knee   synovectomy. 
Excellent hemostasis was achieved with a dose of 54 µg/kg, 
and there were no signs of systemic activation of the coagulation 
system or other adverse events.21 Following this report, a compas-
sionate-use program was put in place and over the next 10 years, 
at least 400 patients were treated with rFVIIa for bleeding epi-
sodes or during surgical procedures.12 Anecdotal case reports 
from the compassionate-use program suggested that rFVIIa 
was effective and safe. There were no anamnestic responses 
reported. Simultaneously, several controlled clinical studies were 
undertaken, all of which were published in 1998.22–24
In a study by Lusher et al patients with congenital 
hemophilia A or B with or without inhibitors were random-
ized in a blinded fashion to receive rFVIIa at doses of either 
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Figure 2c Cell-mediated model with supraphysiologic VIIa. rVIIa can outcompete factor VII for TF binding. Thrombin is generated by the TF: rFVIIa complex and prothrombinase 
as above. This can be inhibited by TFPI. In addition, a burst in thrombin activity is restored by the activation of factor X by rFVIIa present on the surface of activated platelets.
Abbreviations: VIIa, activated Factor VII; rVIIa, recombinant activated Factor VII; TF, tissue factor; TFPI, tissue factor pathway inhibitor.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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35 µg/kg or 70 µg/kg during a joint, muscle, or mucocuta-
neous bleeding episode.22 The study medication was given 
at intervals of 2.5 hours until hemostasis was achieved, or a 
maximum of six doses was given. Response was graded as 
excellent, effective, partially effective, or ineffective. Overall, 
78% and 68% of inhibitor patients with joint bleeds received 
an excellent or effective score for the 35 µg/kg and 70 µg/kg 
doses, respectively. The two dosage regimens showed no sta-
tistically significant differences in response to joint, muscle, 
or mucocutaneous bleeding. Both doses were shown to be 
safe, with no serious adverse events attributable to rFVIIa. 
Although patients with hemophilia who did not have inhibi-
tors also had a good response to rFVIIa, their response was 
felt to be inferior to responses with FVIII or FIX concentrates 
achieved by historic controls. Because patients in this study 
were required to receive the study medication at a treatment 
center, there was a considerable time delay between onset 
of bleeding and the time when the medication was given. To 
control for this, a home treatment study was conducted.
Key et al described a study using rFVIIa in the home 
setting.23 This was an open-label, nonblinded, multicenter, 
single-arm study in hemophilia A and B patients with inhibitors. 
Patients received an infusion of rFVIIa 90 µg/kg within eight 
hours of the onset of a joint, muscle, or mucocutaneous bleed. 
This dose was chosen based on the results of the compassion-
ate-use program. Patients could receive up to two additional 
doses spaced three hours apart until an effective response was 
achieved. An additional maintenance dose of rFVIIa was given 
three hours after an effective response. Using this regimen, 
97% of bleeding episodes were graded as effective or partially 
effective (92% effective) and hemostasis was maintained for 
24 hours in 95% of bleeding episodes. There was one case of 
superficial phlebitis at the infusion site, otherwise no significant 
adverse events were attributed to rFVIIa.
A third study investigated rFVIIa in the surgical setting.24 
This was a double-blind, randomized, multicenter study of 
congenital hemophilia A or B patients with inhibitors and 
nonhemophilic patients with acquired inhibitors undergoing 
major (n = 11) or minor (n = 18) surgery. Patients were ran-
domized to receive rFVIIa 35 µg/kg or 90 µg/kg prior to sur-
gery and at two-hourly intervals thereafter for 48 hours. After 
the first 48 hours, the patients received the study medication 
every 2 to 6 hours for 3 further days. An additional blinded 
dose was allowed at any time if hemostasis was inadequate. 
There was no significant difference in intraoperative bleeding 
or the ability to maintain hemostasis for the first 48 hours 
postoperatively between the two groups. Virtually all the 
patients had adequate hemostasis during the first 48 hours. 
Over the next three days, significantly fewer patients receiv-
ing the 35 µg/kg dose maintained hemostasis, especially 
those undergoing a major surgical procedure. One patient 
developed an internal jugular vein thrombosis at the site of a 
central venous catheter. No other adverse events attributable 
to the study medications were described.
Based on the results of these studies, rFVIIa was approved 
in Europe, the US, and Japan for use in patients with con-
genital or acquired hemophilia and inhibitors. It eventually 
gained approval for use in over 70 countries worldwide.25 
The initial approval recommended a dose of 90 µg/kg given 
every two hours until hemostasis is achieved, or until the 
treatment is judged to be inadequate. For surgical procedures, 
the recommendation is 90 µg/kg given immediately prior 
to surgery, repeated every two hours for 48 hours, and then 
repeated at 2- to 6-hour intervals until healing has occurred. 
Because of the inconvenience of transporting rVIIa and 
storing it at 2–8°C, a new formulation of rFVIIa which can 
be stored at room temperature has become available.25 This 
formulation is available in 1000, 2000, and 5000 µg vials, 
and has a reconstituted concentration of 1000 µg/mL. rFVIIa 
is also approved for use in many countries for patients with 
FVII deficiency, although smaller doses are required to 
achieve hemostasis. In Europe, it is also approved for use in 
Glanzmann’s thrombasthenia.25
The only study to date comparing standard doses of rFVIIa 
with aPCC was published in 2007.26 The FEIBA versus Novo-
seven Comparative (FENOC) study was an open-label, cross-
over equivalence study in which patients with hemophilia 
and inhibitors received standard doses of rFVIIa or aPCC to 
treat joint bleeding. Because of the statistical parameters used 
in the design, this study could not declare the two products 
equivalent, nor could it demonstrate the superiority of either 
agent.26 However, an important outcome of the study was 
the high rate of discordant responses in individual patients 
who had a superior response to one product versus another. 
This suggests that differences in patient variables may lead 
to differences in response to bypassing agents.
Alternative dosing regimens  
for rFVIIa
Continuous infusion
The short half-life of rFVIIa and inconvenience of frequent 
bolus infusions of rFVIIa has led some investigators to 
explore continuous infusion of rFVIIa.27–31 Continuous 
infusion of FVIII or FIX is an established practice to control 
bleeding in hemophilic patients, especially during major 
bleeding events or surgery.28 The potential advantages of Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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continuous infusion are the avoidance of trough levels 
of factor replacement products and a reduced amount of 
coagulation factor replacement usage, leading to a reduced 
financial cost.
The first report of a continuous infusion of rFVIIa was in 
a 62-year-old male with severe hemophilia A and high titer 
inhibitory antibodies.27 Due to ongoing bleeding following 
the surgical repair of an inguinal hernia, he was switched from 
frequent bolus infusions to a continuous infusion of rFVIIa. 
Despite this, bleeding continued and he was eventually res-
cued with porcine FVIII. No relevant preclinical or pharma-
cokinetic studies were described for this patient. Schulman 
et al were the first investigators to describe the successful 
use of a continuous infusion of rFVIIa in 1996.28 Preclinical 
studies were undertaken to confirm the stability and sterility 
of rFVIIa in mini-infusion pump systems. When reconsti-
tuted under laminar air flow, rFVIIa was shown to be stable 
and sterile for at least 3 days. The addition of heparin to the 
reconstituted rFVIIa resulted in a 50% reduction in rFVIIa 
activity within four hours of the addition of heparin. Bonde 
and Bech-Jensen also found reduced activity of rFVIIa after 
mixing with heparin. However, the stability of reconstituted 
rFVIIa was restored if the pH of the heparin solution was 
adjusted to 7.0 prior to mixing with rFVIIa.31 Prior to infus-
ing rFVIIa in patients, Schulman et al then determined the 
pharmacokinetics of rFVIIa in individual patients.28 Based on 
the clearance, patients were infused with a rFVIIa bolus dose 
of 90 µg/kg and given a continuous infusion of rFVIIa, aimed 
at keeping their clotting factor VII activity (FVII:C) level 
at 10 U/mL. Two patients received rFVIIa as a continuous 
infusion during 2 surgical procedures each. Hemostasis was 
achieved for each procedure. One of the patients developed 
thrombophlebitis during his first surgical procedure. During 
his next procedure, low molecular weight heparin was added 
to the reconstituted rFVIIa, with resolution of his throm-
bophlebitis. The amount of rFVIIa used for these procedures 
was estimated to be 50% of that which would have been used 
had the patients received bolus infusions.
Since then, over 25 studies of continuous infusion of rFVIIa 
have been reported.32–37 The majority of reports are open-label, 
nonblinded, uncontrolled case studies or small series. Bolus 
doses range from 75 to 180 µg/kg, and target FVII:C levels 
were 10–30 U/mL. The continuous infusion ranged from 4.7 
to 50 µg/kg/hour. Overall, continuous infusion was reported 
to be successful in over 80% of cases.32 This result should be 
interpreted with caution due to the potential for publication 
bias, in that case studies and small series are more likely to 
be published if they show a positive result.
A review of cases from the Netherlands suggested that 
continuous infusions of rFVIIa may be ineffective for oral 
cavity bleeding.33 Some investigators have suggested that 
higher doses of rFVIIa may be needed to achieve the burst 
of thrombin necessary to achieve hemostasis and have aimed 
for FVII:C levels of greater than 10 U/mL.32,34 However, 
one study which compared higher-dose continuous infusion 
(30 µg/kg/hour) to lower dosing could not demonstrate an 
improved overall hemostatic benefit.35 Another study obtained 
equal efficacy of hemostasis when comparing high-dose 
continuous infusion (50 µg/kg/hour) to bolus infusions of 
90 µg/kg every two hours.36 However, the factor utilization 
in the continuous infusion arm of this study was higher than 
in the bolus group. A third group used high-dose continu-
ous infusion (50 µg/kg/hour), based on previous experience 
with treatment failures using standard continuous infusion 
dosing.37 Although the authors claimed “reasonable hemo-
stasis”, a review of their data revealed that only five of their 
nine patients achieved and maintained hemostasis during 
surgery and for the first 24 hours postoperatively. Only three 
of the nine were able to maintain hemostasis for the entire 
duration of continuous infusion.37 It should be pointed out 
that using continuous infusion of doses of .45 µg/kg/hour 
eliminates any economic advantage over bolus infusions of 
90 µg/kg given every two hours.
Continuous infusion of rFVIIa has been complicated 
by nontrivial thrombophlebitis. This has been alleviated by 
parallel infusions of heparin or saline.
High-dose recombinant activated  
factor VII
Several studies have confirmed that a burst in thrombin activ-
ity is critical for the achievement of normal hemostasis.8,9,15,38 
Doses of rFVIIa 90 µg/kg can achieve plasma FVIIa concen-
trations of 50 nM, and approach the normal burst of thrombin 
during in vitro fibrin clot formation. FVIIa 150 nM appears 
to be necessary to achieve normalization of the thrombin 
burst.38,39 This suggests that higher doses of rFVIIa may be 
necessary to achieve normal thrombin activity in patients with 
hemophilia and inhibitors. Initial anecdotal data suggested 
that this is indeed the case, with several reports of improved 
hemostasis using doses of rFVIIa up to 300 µg/kg.35,40 The 
high doses were well tolerated without thrombotic events 
reported. Based on the in vitro data and the anecdotal reports, 
several studies were initiated to examine the use of high dose 
rFVIIa in hemophilic patients with inhibitors.
In 2005, the Hemophilia and Thrombosis Research Soci-
ety published the results of a review of its database on rFVIIa Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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use.39 Thirty-eight congenital hemophilic patients with 
inhibitors were reviewed for this study. These patients had 
555 bleeding episodes treated with rFVIIa. Bleeding stopped 
in 97% of patients receiving doses of rFVIIa .200 µg/kg 
versus 84% in patients receiving doses ,200 µg/kg. This 
difference was statistically significant. Doses up to 346 µg/kg 
were given without any thrombotic events reported.
A prospective trial of rFVIIa use in the home setting to 
treat hemophiliacs with inhibitors was published by Santa-
gostino in 2005.41 Patients were randomized in an open-label, 
cross-over study to receive either 90 µg/kg, repeated as nec-
essary every three hours, or a single high dose of 270 µg/kg. 
Response was determined using a visual analog scale and was 
equivalent between the two treatment arms over 48 hours of 
assessment. The amount of rFVIIa used did not differ between 
the two groups, nor did the adverse event profile. This study 
demonstrated that a single high dose of rFVIIa could be given 
with efficacy equal to that of repeated standard doses, with 
much greater convenience and similar economic costs.
In another multicenter, randomized, cross-over trial, 
patients were randomized in a blinded fashion to receive 
rFVIIa 270 µg kg followed by two bolus infusions of saline 
three hours apart or rFVIIa 90 µg/kg given every three hours. 
This study also demonstrated equal efficacy with either regi-
men in treating hemarthrosis in the home setting.42
A third randomized, multicenter trial not only compared 
efficacy between standard- and high-dose rFVIIa, but also 
with an aPCC.43 Patients were randomized in a blinded fash-
ion to receive high-dose rFVIIa (270 µg/kg) followed by two 
infusions of saline three hours apart, or standard dose rFVIIa 
given every three hours for three doses. Patients were also 
randomized to a standard dose of aPCC (74 U/kg), but not 
in a blinded fashion due to the appearance and volume of the 
aPCC infusion. The global assessment showed no significant 
difference between the treatment arms, but the aPCC arm was 
statistically more likely to use a rescue medication (36%) than 
the high-dose rFVIIa (8%). Unlike the FENOC study, this 
trial compared high-dose rFVIIa with aPCC and suggested 
an improved response. There were no significant adverse 
events noted with any of the treatment arms.
These studies suggest that high doses of rFVIIa can be 
used with equal efficacy and safety to standard dose rFVIIa, 
but with improved convenience. However, all of the studies 
were hampered by small sample size, with a maximum of 
just over 20 patients in each treatment arm.39,41–43 Given the 
rarity of hemophilic patients with inhibitors, it is doubtful 
that larger studies with improved power to detect statisti-
cal differences between treatments will be undertaken. In 
2007, the European Medicines Agency approved the use of 
single high-dose rFVIIa to treat mild to moderate bleeds in 
hemophilic patients with inhibitors.44
Prophylaxis
One of the principal complications of hemophilia is the 
development of arthropathy due to recurrent hemarthrosis. 
This complication has now been shown to be preventable 
by prophylactic infusions of FVIII or FIX.1 Initial studies of 
prophylaxis used frequent infusions of coagulation factor 
aimed at keeping trough factor levels greater than 1%. Sub-
sequent studies have shown that less frequent infusions may 
be successful in preventing hemarthrosis, suggesting that the 
biologic effect of replacement therapy may be significantly 
longer than any effect measured by laboratory tests.45
Because the half-life of rFVIIa is only two hours, one 
would not intuitively expect this agent to be effective in 
preventing arthritic complications in people with hemophilia 
and inhibitors. Owing to the potential for an extended bio-
logic effect of rFVIIa compared with laboratory measure-
ment, some investigators have been prompted to use rFVIIa 
prophylactically.20,46–49 As with all other uses of rFVIIa, initial 
investigations involved case reports or small series. These 
studies demonstrated a reduction in the number of bleeding 
episodes while patients received prophylactic administration 
of rFVIIa compared with the months preceding its use.
A prospective randomized trial of either 90 µg/kg/day or 
270 µg/kg/day of rFVIIa was done in 38 hemophilic patients 
with inhibitors.50 Bleeding episodes were determined for the 
three months preceding prophylaxis, during three months of 
prophylaxis, and for three months following prophylaxis. The 
number of bleeding episodes during prophylaxis was reduced 
by 45% and 59% with rFVIIa 90 µg/kg and 270 µg/kg, respec-
tively. There was not a statistically   significant difference in 
bleeding reduction between the two groups.   Health-related 
quality of life and quality-adjusted life years were also 
improved by prophylaxis.51 However, the economic burden 
of prophylaxis with rFVIIa is substantial, with annual rFVIIa 
costs potentially exceeding one million dollars per year.46
Safety
Because of the ability of rFVIIa to generate a fibrin clot at 
sites of tissue factor exposure, there is concern that infusions 
of rFVIIa may lead to thromboembolic events. Indeed, reviews 
of the MedWatch Pharmacovigilance of the US Food and Drug 
Agency (FDA) and the FDA Adverse Events Reporting System 
suggested a relatively high rate of thromboembolic events asso-
ciated with rFVIIa use.52,53 However, these reports included both Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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on- and off-label uses. Abshire and Kenet reviewed the preva-
lence of thromboembolic events in patients with congenital or 
acquired hemophilia and inhibitors who received rFVIIa. Their 
initial review covered the years 1996–2003.54 Because use of 
high doses of rFVIIa became more prevalent after 2003, they 
presented an updated review in 2008.55 Overall, over 1.5 mil-
lion doses of rFVIIa were given, with 55 thromboembolic 
events reported. This prevalence of thromboembolic events of 
just under 4/100,000 doses did not seem to differ between the 
two time periods reviewed. Based on these data, it appears that 
rFVIIa is quite safe for use in hemophilic patients with inhibi-
tors, and the risk of thromboembolic events does not appear 
to be increased by high-dose infusions. Off-label use may be 
associated with thromboembolic risk.
Off-label uses of rFVIIa
Although not initially approved for use in FVII deficiency, 
accumulated anecdotal use led to the approval of rFVIIa in 
many parts of the world for treating bleeding episodes in 
patients with FVII deficiency.25 However, because rFVIIa 
is competing with a lower concentration of FVII for tissue 
factor in patients with FVII deficiency, lower doses are used. 
Similar approval has been granted for qualitative platelet 
disorders, specifically Glanzmann’s thrombasthenia.25 Fol-
lowing initial reports of success using rFVIIa in platelet 
disorders and FVII deficiency, rFVIIa was soon found to 
be useful in several clinical bleeding situations including 
trauma, surgical bleeding, obstetric bleeding, intracranial 
hemorrhage, liver disease, hematopoietic stem cell transplant, 
von Willebrand disease, and neonatal bleeding.56,57 A review 
of all of the off-label uses of rFVIIa is beyond the scope of 
this paper, and the reader is referred to several reviews.58–60 
One recent meta-analysis of controlled trials of rFVIIa in 
nonhemophilic bleeding revealed that rFVIIa can reduce the 
number of red cell transfusions, and showed a trend toward 
reducing mortality.61 Overall, the number of thromboembolic 
events were not increased compared with control groups, but 
the number of arterial thrombotic events was statistically 
higher (4.5% versus 2%, respectively).
Modified activated factor VII
Because the short half-life of rFVIIa requires frequent dosing, 
several investigators are pursuing activated FVII molecules 
with improved pharmacokinetic and pharmacodynamic 
properties.62–64 This could provide several advantages, includ-
ing a reduced need for intravenous injections, longer protec-
tion against bleeding episodes, and a reduced amount of 
rFVIIa used. Several strategies have been adopted, including 
a modification of the amino acid sequence of FVII, stabiliza-
tion of the molecule with liposomes or pegylation, or fusion 
proteins with albumin. Investigations into modified rFVIIa 
are in early clinical and preclinical development.
Summary
rFVIIa is a safe alternative to PCCs or aPCCs in the treatment 
of patients with congenital or acquired hemophilia and inhibi-
tors. Using standard doses, it seems to be as effective as aPCCs 
in controlling acute bleeding, and a high dose of rFVIIa may 
be more effective. The principal limitation of this agent is the 
inconvenience of frequent infusions and the economic costs. 
Using high doses of rFVIIa can ameliorate some of the difficul-
ties with frequent dosing. Continuous infusions of rFVIIa may 
alleviate some of the economic costs, although the economic 
benefit is eliminated by using higher doses of continuous infu-
sions. Since controversy remains as to the appropriate dose of 
continuously infused rFVIIa,  this method of infusion at present 
should be reserved for clinical studies. Using rFVIIa prophy-
lactically to prevent bleeding episodes is intriguing, especially 
given its short circulating half-life. However, until additional 
data are available, especially regarding optimal prophylactic 
doses and intervals, the prophylactic use of rFVIIa should also 
be reserved for clinical studies, especially when one considers 
the economic costs of rFVIIa.
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